Advanced Cardiac Therapeutics scores $45M for ablation catheter

human heart
Advanced Cardiac Therapeutics will use its new funding to support a global clinical development program and to seek regulatory approvals for its next-gen ablation catheter.

Advanced Cardiac Therapeutics raised $45 million in equity, which will drive a global clinical development program for its next-generation ablation catheter for the treatment of atrial fibrillation and other arrhythmias.

An irregular heartbeat, atrial fibrillation affects at least 2.7 million Americans, according to the American Heart Association. The condition can lead to blood clots, stroke and heart failure, among other complications. It is treated with catheter ablation, which makes small scars in the heart tissue so that it can no longer carry the arrhythmia.

Advanced Cardiac Therapeutics (ACT) is developing a catheter ablation system that combines temperature control, contact sensing and high-resolution electrogram recording for the treatment of afib.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In addition to funding a clinical development program, the funds will also support bids for regulatory approvals in Europe and the U.S., according to a statement.

“ACT’s continued impressive progress in building a highly differentiated, next generation solution for catheter ablation has been remarkable. We are equally enthusiastic to welcome Ajax and Questa as our financial partners in supporting the ACT team’s efforts to take the treatment of atrial fibrillation to a new level,” said Justin Klein, M.D., a partner at New Enterprise Associates, which led the financing alongside Ajax Health and Questa Capital Management.

In March, CardioFocus and MedLumics both reeled in some funding for their ablation catheters. The former netted $20 million to boost the commercialization of its endoscopic ablation system, while the latter bagged $37 million to support clinical trials of its optically guided ablation catheter.

Meanwhile, San Diego-based Acutus Medical is working on an ablation system that tracks a patient’s arrhythmia in real time and provides the electrophysiologist with a three-dimensional view of the heart's atrium and its electrical activity. The company seeks to substantially improve the success rate of ablation procedures, which currently rely on low-resolution, voltage-based mapping.

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.